Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight

Reuters03-27 20:45

Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight

Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Attune Biotech and SGP Holdings.
The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122 (Lodonal) immune restoration platform.
Callan JMB’s scope includes independent validation of manufacturing, quality systems, and supply chain operations as the program advances toward Phase 2b/3 development.
The work also includes alignment with federal standards associated with BARDA, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270845PRIMZONEFULLFEED9679473) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622821978?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622821978","market":"us","top_or_hot":-1,"title":"Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Attune Biotech and SGP Holdings.\n        </li>\n<li>\n          The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122 (Lodonal) immune restoration platform.\n        </li>\n<li>\n          Callan JMB’s scope includes independent validation of manufacturing, quality systems, and supply chain operations as the program advances toward Phase 2b/3 development.\n        </li>\n<li>\n          The work also includes alignment with federal standards associated with BARDA, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CJMB\">Callan JMB Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270845PRIMZONEFULLFEED9679473) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCallan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Attune Biotech and SGP Holdings.\n        </li>\n<li>\n          The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122 (Lodonal) immune restoration platform.\n        </li>\n<li>\n          Callan JMB’s scope includes independent validation of manufacturing, quality systems, and supply chain operations as the program advances toward Phase 2b/3 development.\n        </li>\n<li>\n          The work also includes alignment with federal standards associated with BARDA, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CJMB\">Callan JMB Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270845PRIMZONEFULLFEED9679473) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2V16.EUR","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2BDbgr:1","article_id":"2622821978","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622821978","pubTimestamp":1774615527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight. Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Attune Biotech and SGP Holdings.The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122  immune restoration platform.Callan JMB’s scope includes independent validation of manufacturing, quality systems, and supply chain operations as the program advances toward Phase 2b/3 development.The work also includes alignment with federal standards associated with BARDA, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4131":"航空货运与物流","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","CJMB":"Callan JMB Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC"},"translate_title":"Callan JMB加入DifGen、Aveva、Attune Biotech、SGP开展JKB-122免疫平台扩大合作；提供独立的制造和供应链监督","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CJMB":0.9,"NDAQ":0.9},"content_text":"Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight\n    \n\n\n          Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Attune Biotech and SGP Holdings.\n        \n\n          The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122 (Lodonal) immune restoration platform.\n        \n\n          Callan JMB’s scope includes independent validation of manufacturing, quality systems, and supply chain operations as the program advances toward Phase 2b/3 development.\n        \n\n          The work also includes alignment with federal standards associated with BARDA, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270845PRIMZONEFULLFEED9679473) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622821978","isCrawlerRequest":true}